Beer four essence

Según un estudio realizado por Euromonitor Internacional en mayo del 2013 sobre las tendencias en bebidas alcohólicas mostro que el consumo de cerveza en Colombia es de 2.194,7 millones de litros; esto se relaciona con los nuevos gustos y tendencias en el mercado colombiano se conocen de estudios que han demostrado que no tener una dieta balanceada, junto a no realizar actividad física constante y consumir cerveza de forma excesiva pueden generar un alto nivel de glucosa y calorías (Salud O. M., 2015). Conocer cómo se elabora la cerveza y los ingredientes como la cebada, lúpulo, levadura, si no se consume adecuadamente puede tener consecuencias en la salud del consumidor, pero de igual forma una investigación titulada El estudio de las bases científicas de los efectos beneficiosos del consumo moderado de cerveza sobre el sistema cardiovascular: efectos antiinflamatorios del contenido en alcohol y polifenoles de la cerveza, realizada en la Universidad de Barcelona (UB) y el Hospital Clínico de Barcelona en el 2011 indica que la cerveza es fuente de vitaminas, hierro calcio y ácido fólico, junto con los beneficios cardiovasculares que necesarios para mantener un estado óptimo de salud

Beer four essence

Según un estudio realizado por Euromonitor Internacional en mayo del 2013 sobre las tendencias en bebidas alcohólicas mostro que el consumo de cerveza en Colombia es de 2.194,7 millones de litros; esto se relaciona con los nuevos gustos y tendencias en el mercado colombiano se conocen de estudios que han demostrado que no tener una dieta balanceada, junto a no realizar actividad física constante y consumir cerveza de forma excesiva pueden generar un alto nivel de glucosa y calorías (Salud O. M., 2015). Conocer cómo se elabora la cerveza y los ingredientes como la cebada, lúpulo, levadura, si no se consume adecuadamente puede tener consecuencias en la salud del consumidor, pero de igual forma una investigación titulada El estudio de las bases científicas de los efectos beneficiosos del consumo moderado de cerveza sobre el sistema cardiovascular: efectos antiinflamatorios del contenido en alcohol y polifenoles de la cerveza, realizada en la Universidad de Barcelona (UB) y el Hospital Clínico de Barcelona en el 2011 indica que la cerveza es fuente de vitaminas, hierro calcio y ácido fólico, junto con los beneficios cardiovasculares que necesarios para mantener un estado óptimo de salud

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective